Risk of HBV Reactivation According to Viral Status and Treatment Intensity in Patients with Hepatocellular Carcinoma

Abstract

Background

There are no convincing data supporting the routine use of pre-emptive therapy against HBV reactivation in various loco-regional therapies for hepatocellular carcinoma (HCC). This study investigated the incidence, severity and risk factors of HBV reactivation during loco-regional therapies.

Methods

A total of 205 prospectively enrolled patients were classified in order of increasing intensity of loco-regional therapies: local ablation therapy (LAT; 43 patients), transarterial chemotherapy using adriamycin (TAC-ADR; 93 patients) or combined epirubicin-cisplatin (TAC-EC; 26 patients), and combined chemo-radiotherapy (TAC-EC+RT; 43 patients).

Results

During the follow-up, 62 (30.2%) patients developed HBV reactivation. Multivariate analysis identified HBV DNA levels >10⁴ copies/ml (P=0.041) and treatment option (P=0.001) to be independent predictors of HBV reactivation. There was a significant trend for increasing risk of reactivation with increasing intensity of therapy, with hazard ratios of 1.0 for LAT, 2.45 for TAC-ADR, 4.19 for TAC-EC and 10.17 for TAC-EC+RT. The severity of reactivated disease was also increased with increasing treatment intensity (P-value for trend <0.05). Only one of the patients with low-level viraemia receiving LAT alone developed reactivation, whereas a substantial number of patients with high-level viraemia eventually developed reactivation.

Conclusions

High-level viraemia and high-level treatment intensity are the major risk factors for HBV reactivation during loco-regional therapy. Trends are evident for the increased risk and severity of reactivation with the aggressiveness of treatment. Pre-emptive antiviral therapy should be recommended for all patients with high-level viraemia irrespective of treatment option, or those undergoing any intensive therapy.

References

Bosch

F.X.

, Ribes

, Borras

Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271–285.

Nagamatsu

, Kumashiro

, Itano

Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003; 26: 293–301.

Jang

J.W.

, Choi

J.Y.

, Bae

S.H.

Transarterial chemorlipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427–435.

Yeo

, Lam

K.C.

, Zee

Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661–1666.

Yeo

, Johnson

P.J.

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.

Liaw

Y.F.

, Leung

, Guan

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472–489.

You

C.R.

, Jang

J.W.

, Kang

S.H.

[Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis]. Korean J Hepatol 2007; 13: 378–386. Korean.

10.

Jang

J.W.

, Kay

C.S.

, You

C.R.

Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int J Radiat Oncol Biol Phys 2009; 74: 412–418.

11.

Jang

J.W.

, Park

Y.M.

, Bae

S.H.

Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 415–420.

12.

Jang

J.W.

, Choi

J.Y.

, Bae

S.H.

A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233–240.

13.

Park

J.W.

, Park

K.W.

, Cho

S.H.

Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005; 100: 2194–2200.

14.

Kusumoto

, Tanaka

, Mizokami

, Ueda

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13–23.

15.

Lau

G.K.

Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2: 152–162.

16.

Lau

G.K.

, Leung

Y.H.

, Fong

D.Y.

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324–2330.

17.

Zhong

, Yeo

, Schroder

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55–59.

18.

Keeffe

E.B.

, Dieterich

D.T.

, Han

S.H.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315–1341.

19.

Kim

J.H.

, Park

J.W.

, Kim

T.H.

Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 813–819.

20.

Chou

C.H.

, Chen

P.J.

, Lee

P.H.

Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin Cancer Res 2007; 13: 851–857.

21.

Hoofnagle

J.H.

Reactivation of hepatitis B. Hepatology 2009; 49: S156–S165.

22.

, Mellander

, Andersson

, Abrahamsson

Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005; 44: 461–468.

23.

Mindikoglu

A.L.

, Regev

, Schiff

E.R.

Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076–1081.

24.

Perrillo

R.P.

Acute fares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009–1022.

25.

Levy

, Marcellin

, Martinot-Peignoux

Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 1990; 12: 570–574.

26.

Tseng

T.C.

, Liu

C.J.

, Wang

C.C.

Serum hepatitis B virus DNA level at one year after hepatitis B e antigen seroconversion predicts subsequent hepatitis B reactivation. J Hepatol 2009; 50: S145.